Prescriptions of newer glucose regulating agents in older hospitalized patients with type 2 diabetes A retrospective cohort study

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2023-10-01 DOI:10.1016/j.deman.2023.100157

Drs. Merel L.J.M. Janssen , Dr. Carolien M.J. van der Linden , Dr. Maarten J. Deenen , Dr. Petra E. Spies , Drs. Anne Jacobs

{"title":"Prescriptions of newer glucose regulating agents in older hospitalized patients with type 2 diabetes A retrospective cohort study","authors":"Drs. Merel L.J.M. Janssen , Dr. Carolien M.J. van der Linden , Dr. Maarten J. Deenen , Dr. Petra E. Spies , Drs. Anne Jacobs","doi":"10.1016/j.deman.2023.100157","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><p>GLP-1-analogues, DPP4-inhibitors, and SGLT2-inhibitors have become available to treat type 2 diabetes. The extent to which these glucose regulating agents (GRA) are prescribed to older patients is unknown.</p></div><div><h3>Methods</h3><p>We performed a retrospective observational cohort study including all clinical admissions of patients with one or more prescriptions for non-insulin GRA between 2017 and 2021. We analyzed prescription trends and differences in prescription prevalences for frail and non-frail older patients, as well as older (≥ 70 years) versus younger patients.</p></div><div><h3>Results</h3><p>In total 11.5% of admissions had one prescription or more of newer GRA; GLP-1-analogues 1.6%, DPP4-inhibitors 7.3% and SGLT2-inhibitors 2.3%. Total prescription prevalence increased from 8.4% to 16.3% (<em>p</em> < 0.001). Prescription prevalence was 11.1% (<em>N</em> = 129) in admissions of frail patients versus 14.6% (<em>N</em> = 344) of non-frail patients (<em>p</em> = 0.005) and 15.0% in admissions of younger patients versus 11.5% of older patients (<em>p</em> < 0.001).</p></div><div><h3>Conclusions</h3><p>Prescription prevalence of newer GRA in clinical admissions of older patients (≥ 70 years) increased from 2017 to 2021. Prevalence was lower in admissions of frail and older patients, possibly because they are undertreated due to a lack of clear recommendations for older patients in guidelines and underrepresentation in clinical trials.</p></div>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266697062300029X","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

GLP-1-analogues, DPP4-inhibitors, and SGLT2-inhibitors have become available to treat type 2 diabetes. The extent to which these glucose regulating agents (GRA) are prescribed to older patients is unknown.

Methods

We performed a retrospective observational cohort study including all clinical admissions of patients with one or more prescriptions for non-insulin GRA between 2017 and 2021. We analyzed prescription trends and differences in prescription prevalences for frail and non-frail older patients, as well as older (≥ 70 years) versus younger patients.

Results

In total 11.5% of admissions had one prescription or more of newer GRA; GLP-1-analogues 1.6%, DPP4-inhibitors 7.3% and SGLT2-inhibitors 2.3%. Total prescription prevalence increased from 8.4% to 16.3% (p < 0.001). Prescription prevalence was 11.1% (N = 129) in admissions of frail patients versus 14.6% (N = 344) of non-frail patients (p = 0.005) and 15.0% in admissions of younger patients versus 11.5% of older patients (p < 0.001).

Conclusions

Prescription prevalence of newer GRA in clinical admissions of older patients (≥ 70 years) increased from 2017 to 2021. Prevalence was lower in admissions of frail and older patients, possibly because they are undertreated due to a lack of clear recommendations for older patients in guidelines and underrepresentation in clinical trials.

查看原文本刊更多论文

老年住院2型糖尿病患者新型血糖调节剂处方的回顾性队列研究

glp -1类似物、dpp4抑制剂和sglt2抑制剂已可用于治疗2型糖尿病。这些葡萄糖调节剂(GRA)在多大程度上适用于老年患者尚不清楚。方法:我们进行了一项回顾性观察性队列研究，纳入了2017年至2021年间所有临床入院的非胰岛素类GRA处方患者。我们分析了体弱多病和非体弱多病老年患者的处方趋势和处方患病率的差异，以及老年(≥70岁)和年轻患者的处方患病率差异。结果11.5%的住院患者有一个或多个较新的GRA处方;glp -1类似物1.6%，dpp4抑制剂7.3%，sglt2抑制剂2.3%。处方总患病率从8.4%增加到16.3% (p <0.001)。入院的体弱患者处方患病率为11.1% (N = 129)，非体弱患者为14.6% (N = 344) (p = 0.005);入院的年轻患者为15.0%，老年患者为11.5% (p <0.001)。结论2017年至2021年，老年患者(≥70岁)临床入院中使用新型GRA的比例有所上升。入院的体弱和老年患者患病率较低，可能是因为指南中缺乏针对老年患者的明确建议以及临床试验中代表性不足，导致他们未得到充分治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.